BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.140
-0.020 (-1.72%)
At close: Apr 28, 2026, 4:00 PM EDT
1.140
0.00 (0.00%)
Pre-market: Apr 29, 2026, 8:09 AM EDT
BioCardia Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
12.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCDA News
- 9 days ago - BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure - GlobeNewsWire
- 5 weeks ago - BioCardia Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - BioCardia Reports 2025 Business Highlights and Financial Results - GlobeNewsWire
- 5 weeks ago - BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - GlobeNewsWire
- 2 months ago - BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart - GlobeNewsWire
- 4 months ago - BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA - GlobeNewsWire
- 5 months ago - BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - GlobeNewsWire
- 5 months ago - BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - GlobeNewsWire